Pyxis Oncology Inc PYXS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-08 |
| Shares Out. | 82,960,000 |
| Website | pyxisoncology.com/ ↗ |
| Phone | 16172219059 |
| Employees | 56 |
| Net Income | -$23.3M |
| Free Cash Flow | -$67.0M |
| Total Assets | $64.3M |
| Total Liabilities | $33.0M |
| Equity | $31.3M |
About Pyxis Oncology Inc
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Pyxis Oncology Inc is a publicly traded company under the ticker symbol PYXS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)